HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Marksans Pharma Ltd Stock Comparison

Cohance Lifesciences Ltd vs Marksans Pharma Ltd Stock Comparison

Last Updated on: May 27, 2025

Key Highlights

  • The Latest Trading Price of Suven Pharmaceuticals Ltd is ₹ 1092 as of 27 May 15:30.
  • The P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 yearsThe P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 21.9 on March 2024 . This represents a CAGR of 36.04% over 5 years.
  • The Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 yearsThe Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 6867 crore on March 2024 . This represents a CAGR of 64.57% over 5 years.
  • The revenue of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the decline of -100% The revenue of Marksans Pharma Ltd for the Mar '25 is ₹ 724.98 crore as compare to the Dec '24 revenue of ₹ 709.7 crore. This represent the growth of 2.15%.
  • The ebitda of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -100% The ebitda of Marksans Pharma Ltd for the Mar '25 is ₹ 142.27 crore as compare to the Dec '24 ebitda of ₹ 166.61 crore. This represent the decline of -14.61%.
  • The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 90.73 crore over 8 quarters. This represents a CAGR of 13.49% .
  • The Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 20.33 % on March 2024 . This represents a CAGR of 13.49% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

Marksans Pharma Ltd News Hub

News

Board of Marksans Pharma recommends final dividend

Marksans Pharma announced that the Board of Directors of the Company at its meeting held o...

Read more

20 May 2025 12:49

News

Relonchem receives marketing authorization for Sennosides 7.5 mg tablets

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

19 May 2025 13:29

News

Relonchem receives marketing authorization for Gabapentin 50 mg/ml oral solution

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

15 May 2025 09:45

News

Marksans Pharma to conduct board meeting

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 19 May 202...

Read more

08 May 2025 15:09

News

USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York

Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection wa...

Read more

28 Apr 2025 12:58

News

Marksans Pharma gains as USFDA concludes inspection at New York unit

The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturi...

Read more

28 Apr 2025 11:56

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Suven Pharmaceuticals Ltd and Marksans Pharma Ltd

Which company has a larger market capitalization, Suven Pharmaceuticals Ltd or Marksans Pharma Ltd?

Market cap of Suven Pharmaceuticals Ltd is 27,815 Cr while Market cap of Marksans Pharma Ltd is 11,417 Cr

What are the key factors driving the stock performance of Suven Pharmaceuticals Ltd and Marksans Pharma Ltd?

The stock performance of Suven Pharmaceuticals Ltd and Marksans Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suven Pharmaceuticals Ltd and Marksans Pharma Ltd?

As of May 27, 2025, the Suven Pharmaceuticals Ltd stock price is INR ₹1092.65. On the other hand, Marksans Pharma Ltd stock price is INR ₹251.95.

How do dividend payouts of Suven Pharmaceuticals Ltd and Marksans Pharma Ltd compare?

To compare the dividend payouts of Suven Pharmaceuticals Ltd and Marksans Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions